Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.01 is 941% above its 3-year average of 0.00, near the high end of its 3-year range (-0.02–0.01).
As of the fiscal period ended Tuesday, June 30, 2026. 72.64% above its 12-month average of 0.01.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
DEBT TO EQUITY RATIO
0.01
DEBT TO EQUITY RATIO AVG TTM
0.01
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+72.64%
CURRENT VS 3Y AVG
+940.63%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-91.77%
vs the sector median at left
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$109.86M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.00
5Y Avg
N/A
Market Cap
$111.72M
Debt to Equity Ratio
N/A
TTM Avg
0.12
3Y Avg
0.14
5Y Avg
0.21
Market Cap
$112.42M
Debt to Equity Ratio
N/A
TTM Avg
230.24
3Y Avg
153.68
5Y Avg
153.68
Market Cap
$113.07M
Debt to Equity Ratio
0.01
TTM Avg
0.06
3Y Avg
0.06
5Y Avg
0.04
Market Cap
$109.49M
Debt to Equity Ratio
3.72
TTM Avg
2.72
3Y Avg
1.72
5Y Avg
1.15
Market Cap
$114.27M
Debt to Equity Ratio
2.28
TTM Avg
3.15
3Y Avg
2.13
5Y Avg
1.28
Market Cap
$114.34M
Debt to Equity Ratio
0.15
TTM Avg
0.11
3Y Avg
0.12
5Y Avg
0.12
Market Cap
$109.38M
Debt to Equity Ratio
0.27
TTM Avg
0.66
3Y Avg
0.63
5Y Avg
0.55
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $109.86M | 0.01 | 0.01 | 0.00 | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $111.72M | N/A | 0.12 | 0.14 | 0.21 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.42M | N/A | 230.24 | 153.68 | 153.68 |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $113.07M | 0.01 | 0.06 | 0.06 | 0.04 |
| Apyx Medical Corporation (APYX)vs › | $109.49M | 3.72 | 2.72 | 1.72 | 1.15 |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | 0.11 | 0.10 | 0.08 | 0.09 |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.27M | 2.28 | 3.15 | 2.13 | 1.28 |
| Genelux Corporation (GNLX)vs › | $114.34M | 0.15 | 0.11 | 0.12 | 0.12 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $109.38M | 0.27 | 0.66 | 0.63 | 0.55 |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.88M | 0.27 | 0.16 | 0.12 | 0.10 |
Debt/Equity
0.01
Current Ratio
12.63
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.01 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | -0.01 |
| 2024-09-30 | -0.02 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
